Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.
about
Chest computed tomography predicts the frequency of pulmonary exacerbations in children with cystic fibrosis.Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosisTreatment Trials for Neonatal Seizures: The Effect of Design on Sample Size.IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosisAccurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations.Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis: Randomized, Controlled, Multicenter Trial.
P2860
Q33783243-3E828AD5-2100-4A97-868B-AB68C96D3961Q33836925-6F67A229-3CFA-4477-BF1B-6640E54F800AQ34324105-BCAF4769-F1A9-40A9-90F3-42D319C93583Q35801062-73EECD04-B68E-4374-A40C-177B41FB4DF7Q36031045-44A64572-B177-40E1-9834-BC9FD3A81167Q36185702-0499353D-DCAC-4E74-9B15-6E5172DD1BD5Q36827488-44202A2F-7901-4816-B8EC-1B8AB04979EDQ36944153-D6514B73-2A9E-4CAE-93AE-E0E5AF194AA0Q37568497-4CB6304E-B461-4709-B61E-3949D7D3A9D9Q38543069-C450FB85-9664-4CA7-8953-B5ED15428D35Q38657567-B778D2C8-3320-4D6A-A4B5-777D57A0C228Q44016904-EB3D3FAE-CF7F-4476-9303-86506BDF173BQ52567103-0F3845D4-3BB0-4369-AFEC-8315B72E54DA
P2860
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Design and powering of cystic ...... ation as an efficacy endpoint.
@ast
Design and powering of cystic ...... ation as an efficacy endpoint.
@en
type
label
Design and powering of cystic ...... ation as an efficacy endpoint.
@ast
Design and powering of cystic ...... ation as an efficacy endpoint.
@en
prefLabel
Design and powering of cystic ...... ation as an efficacy endpoint.
@ast
Design and powering of cystic ...... ation as an efficacy endpoint.
@en
P2093
P2860
P1476
Design and powering of cystic ...... bation as an efficacy endpoint
@en
P2093
P2860
P304
P356
10.1016/J.JCF.2011.07.003
P577
2011-07-30T00:00:00Z